The dysregulation of gene expression is an enabling hallmark of cancer. Computational analysis of 26 transcriptomics data from human cancer specimens, complemented with exhaustive clinical annotation, 27
Introduction 40
Balanced integration of intracellular circuits operates within a normal cell to sustain physiological 41 homeostasis. Alterations in some, if not all, of these circuits converge in changes on gene expression, 42 which will eventually enable the acquisition and sustenance of the hallmarks of cancer cells (1). This 43 event emphasizes the importance of maintaining the transcriptional homeostasis in normal cells and 44 places gene expression deregulation at the core of cancer research interests. 45
In the last decades, transcriptomics data derived from cancer specimens has become an important 46 resource for the classification, stratification and molecular driver identification in tumors. We and others 47 lineage (19) . The existence of different MITF transcript variants is the result of both alternative splicing 66 and promoter activation that results in the cell-type-specific expression of the different MITF isoforms 67 (A, CX, MC, C, E, H, D, B, M, J) (20) . The melanoma specific isoform M-MITF is the best studied isoform 68 and, despite some controversy, its expression is generally deregulated in melanoma. Although MITF 69 alone cannot act as a classical oncogene, it has been called a 'lineage survival oncogene' for melanoma 70 (19, 21) . Importantly, the presence or absence of the M-MITF-PGC1α regulatory axis has stratification 71 potential in melanoma and informs on the efficacy of BRAF inhibitor treatments (18, 22) . Although the 72 expression of MITF has been detected in other types of tumors different from melanoma (23, 24) , its 73 active role in the progression of these diseases, including PCa, remains unexplored. 74
Crystallin Alpha-B (CRYAB) is a ubiquitous small heat shock protein that is expressed in response to a 75 wide range of physiological and non-physiological conditions preventing aggregations of denatured 76 proteins. In a wide variety of tumor types CRYAB has been found to be overexpressed and associated 77 with disease progression (25-29) and poor prognosis (30, 31) . However, in PCa and nasopharyngeal 78 cancers CRYAB expression is decreased (32, 33) , pointing at possible tumor suppressive activity of 79 CRYAB in these cancer scenarios. 80
In the present study, by combining an exhaustive interrogation of seven publically available prostate 81 cancer databases with refined empirical assays, we have identified MITF as a prostate tumor 82
suppressor. In addition, we have unveiled CRYAB as a novel direct target of the transcription factor that 83 is, at least in part, responsible for its tumor suppressive activity in prostate cancer. Importantly, the 84 tumor suppressive role for this novel MITF-CRYAB axis is supported by the enhanced prognostic 85 potential of a signature based on the concomitant alteration of both genes in PCa patients. 86
Results

87
Bioinformatics screening identifies MITF as a transcription factor altered in prostate cancer 88
We have recently demonstrated that the reduced expression of the transcriptional co-activator PGC1α 89 is a causal event for metastatic prostate cancer (PCa) (14) . We sought to identify transcriptional 90 regulators related to the alteration in PGC1α expression. We designed a bioinformatics strategy based 91 on the analysis of 16 genes directly linked to the regulation of PGC1A gene (17, 22, (34) (35) (36) (37) (38) , in order to 92 identify transcription factors that could be relevant to PCa biology. For the candidate screen we applied 93 selection criteria based on the consistency of, first, the correlation with PGC1A expression and second, 94 the expression of each individual candidate in seven publicly available PCa datasets (7, 9-13) ( Figure  95 1 A). We selected those candidates whose expression in primary tumors correlated with PGC1A (R ≥ 96 0.2 and p-value ≤ 0.05 in more than 50% of the datasets) ( Supplementary Figure 1 A) and was altered 97 when compared to normal specimens. For genes exhibiting various transcript variants, the correlation 98 analysis was initially performed using the average signal ( Supplementary Figure 1 A) and, when 99 available (only Taylor dataset (11)), the correlation was confirmed in all the individual isoforms 100
( Supplementary table 1 ). The transcription factor MITF was the sole candidate that complied with the 101 established criteria. We observed a consistent correlation between PGC1A and MITF in four out of the 102 seven datasets analyzed (Figure 1 B and Supplementary Figure 1 A) . In addition, not only the mean 103 expression but also the expression of the individual MITF isoforms were reduced in primary and 104 metastatic PCa specimens when compared with the normal prostate tissue samples (Figure 1 C and 105 Supplementary Figure 1 B ). Taken together, our data reveals MITF as a PGC1A-associated 106 transcription factor that is consistently downregulated in PCa. 107
108
MITF exhibits tumor suppressive activity in PCa 109
The expression profile of MITF in PCa, together with its direct correlation with PGC1A, was suggestive 110 of a tumor suppressive activity of the transcription factor. We first examined the differential expression 111 of the distinct mRNA isoforms of MITF in normal, PCa primary tumors and PCa cell lines 112 ( Supplementary Fig. 2 A-C). MITFA was the isoform predominantly expressed in the three scenarios 113 analyzed, and we pursued the studies further with this isoform. Next, we aimed to analyze the biological 114 consequences of ectopic expression of MITFA in PC3 PCa cells. We transduced PC3 cells with a 115 lentiviral vector containing a doxycycline-inducible cassette for the expression of MITFA resulting in the and identified 101 probes that showed statistically differential signal between both conditions 140 (Supplementary table 2). We first performed a gene enrichment analysis with those genes which 141 displayed upregulated expression (76 genes) upon MITFA over-expression ( Figure 3 A and 142 Supplementary table 3) , as the number of downregulated genes (25) was no sufficient to obtain any 143 gen enrichment. Next, we aimed at identifying potential MITFA effectors of relevance in human PCa. 144
To this end, we established a threshold of 1.5 fold change over MITFA non-induced cells, which resulted 145 in 8 probes (corresponding to 6 annotated genes) upregulated upon the induction of the transcription 146 factor (Supplementary table 2; yellow bold highlighted). We next performed correlation analysis 147 between MITF and each of the 6 differentially expressed genes obtained from the microarray ( Figure 3 Taken together, these data presented CRYAB as a direct target of MITFA and the best candidate to 166 mediate its tumor suppressive activity in PCa. 167
168
CRYAB mediates the tumor suppressive activity of MITF in PCa 169
We next studied the functional relevance of CRYAB for the tumor suppressive activity of MITFA in PCa. 170
Towards this aim, we constitutively silenced the expression of CRYAB by RNAi using two independent 171 short hairpin RNA (sh#1 and sh#2) in PC3 TRIPZ-MITFA cells. After validation that RNAi was achieved 172 CRYAB is a major effector involved in the tumor suppressive activity of the transcription factor MITF in 180
PCa. 181
We next asked whether the functional association between MITF and CRYAB could be employed to 182 identify PCa patients with high disease aggressiveness. We thus ascertained the stratification potential 183 of the MITF-CRYAB axis in PCa by means of consistency and robustness. We download the mRNA 184 expression raw data together with the clinical data (recurrence or not recurrence) from Taylor (11), 185 Glinsky (8) in the way that we combat the disease. We are now able to deconstruct a tumor at a molecular level 199 using genomics, transcriptomics, proteomics and metabolomics. This, in turn, enables us to foresee, 200 identify and demonstrate the potential of patient stratification. Specifically, the transcriptomics 201 characterization of tumors is an invaluable strategy to identify clinically relevant genes that play key 202 roles in the progression of cancer, especially for those types with poorer prognosis (14). Thus, the 203 comprehensive and integrative analysis of gene expression changes and clinical parameters in cancer 204 has become a mainstream in cancer research. Mining cancer-associated transcriptome datasets is an 205 emerging approach used by top cancer research groups, but better tools are needed to increase its 206 power and user-friendliness. In order to face this challenge, new interfaces to exploit OMICs data, such 207 as cBioportal (40, 41) are being designed to help scientists interrogate, integrate and visualize large 208 amount of information contained on multiple credible and qualified cancer datasets. 209
In the present study, we exploited publicly available and well-annotated (transcriptomics and clinical 210 data) prostate cancer databases together with experimental assays to describe a novel tumor 211 suppressive activity of the transcription factor MITF in PCa, which is executed, at least in part, through 212 the direct regulation of the CRYAB expression. 213
The functional implication of MITF in cancer has been best defined in melanoma, in which the 214 expression of the transcription factor is heterogeneous. Although some controversy exists regarding its 215 oncogenic role in melanoma, MITF has been defined as a "lineage survival oncogene" with no data 216 pointing out at a tumor suppressive function (19, 21, 39, (42) (43) (44) (45) . Even though the expression of MITF 217 has been detected in other cancer types (23, 24, 46) , no data supporting a functional role of MITF 218 deregulation has been reported yet in a cancer scenario different from melanoma. 219
Here we show that MITF is downregulated in PCa when compared with normal specimens, in contrast 220 to the elevated expression reported in hepatocellular carcinoma (HCC) and chronic myeloid leukemia 221 (CML) (23, 46) . Moreover, the novelty of our study relies on the observation and definition of the tumor 222 suppressive activity of MITF in PCa. In this context, MITFA upregulation was associated with a reduction 223 in cell proliferation and DNA replication. As occurs in melanoma, the modulation of MITF expression in 224
PCa cells induces the expression of the cell cycle inhibitor p21 but no changes in the cell cycle inhibitor 225 p16 were observed (data not shown). Thus, our results in PCa are in line with the canonical function of 226 MITF in cell cycle progression and proliferation in melanoma (39, 44, 45) . 227
It's important to highlight that the tissue specific differences in MITF expression among different cancer 228 types suggest that in order to fully comprehend MITF's role in cancer, its expression and function has 229 to be analyzed in context of each particular cell and tissue type. 230
CRYAB is a member of the small heat shock protein family that functions as stress-induced molecular 231 chaperone. It inhibits the aggregation of denatured proteins, promotes cell survival and inhibits 232 apoptosis in the context of cancer (47). Paradoxically, CRYAB is highly expressed in some cancer types 233 but decreased in others and in both scenarios an association with cancer progression and prognosis 234 has been reported (25, 26, (28) (29) (30) (31) (32) (48) (49) (50) (51) (52) . In spite of the amount of information regarding the changes 235 in CRYAB expression in cancer, the transcriptional regulation of this chaperone has been poorly 236 explored (48). In this study, we described a novel direct transcriptional regulation of CRYAB by MITF. 237
Although there is no direct nor mechanistic evidence of the MITF-CRYAB transcriptional axis in other 238 cancer types, in melanoma both MITF and CRYAB expression are upregulated by BRAF/MEK-inhibitor 239 treatments (49, 52), suggesting that this regulation can go beyond both prostate cancer scenario. 240
Indeed, we observed that the correlation between MITF and CRYAB is also present in colorectal cancer, 241
but not in breast nor lung cancer (data not shown). 242
In our study, the MITF-CRYAB transcriptional axis is reduced and exerts tumor suppressive activity in 243
PCa. This is in agreement with the reduced expression of CRYAB observed in PCa patients and its 244 previous consideration as a protective gene against PCa (32). Yet, the exact molecular mechanism 245 underlying the tumor suppressive activity of CRYAB remains to be elucidated. 246
Importantly, the extensive interrogation of PCa transcriptomes and associated clinical data has led us 247 to propose the transcriptional axis MITF-CRYAB as a potential prognostic biomarker in PCa. The 248 individual expression of CRYAB and MITF has been previously associated with poor prognosis in 249 various tumor types (26, 29-31, 50, 51) and to therapy response in melanoma (53-55). However, our 250
data showing enhanced prognostic potential of the combined signature provides a new and exciting 251 perspective of the functional interaction of these genes in PCa. 252
Our study endorses the potential of transcriptional deregulation analysis, as either a cause or a 253 consequence of cancer, and its impact to support the discovery of novel cancer related genes and long-254 term development of novel cancer treatment strategies. 255
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Xenotransplant assays 290
All mouse experiments were carried out following the ethical guidelines established by the Biosafety 291
and Welfare Committee at CIC bioGUNE. The procedures employed were carried out following the 292 recommendations from AAALAC. Xenograft experiments were performed as previously described (14), 293 injecting 10 6 cells per condition in two flanks per mouse (Nu/Nu immunodeficient males; 6-12 weeks of 294 age). PC3 TRIPZ-HA-MITFA cells alone or under CRYAB silencing were injected in each flank of nude 295 mice and 24 h post-injections mice were fed with chow or doxycycline diet (Research diets, 296 D12100402). 297
Patient samples 298
All samples were obtained from the Basque Biobank for research (BIOEF, Basurto University hospital) 299 upon informed consent and with evaluation and approval from the corresponding ethics committee 300 (CEIC code . 301
Molecular assays 302
Western blot was performed as previously described (14 
Cellular assays 317
Cell number quantification with crystal violet was performed as referenced (14). 318
For starvation experiments 100,000 cells per well were seeded in a 6-well plate. Cells were initially 319 plated in 10% FBS media for 24 hours and then the media was changed to FBS free media and left 320
overnight. 321
Soft agar assays were performed as previously described (14), seeding 5,000 cells per well in 6-well 322
plates. 323
For BrDu incorporation, cells were seeded on glass cover slips in 12-well plates and after 4 days, cells 324 were incubated with 3 µg mL -1 BrDu (Sigma B5002). Cells were fixed with 4% para-formaldehyde, 325 permeabilized with 1% Triton X-100 and incubated with a monoclonal anti-BrDu (MoBU-1) antibody 326 (Invitrogen B35128) at a 1:100 dilution. Images were obtained with an AxioImager D1 microscope 327 (Zeiss). At least three different areas per cover slip were quantified. 328
Chromatin Immunoprecipitation 329
Chromatin Immunoprecipitation (ChIP) was performed using the SimpleChIP ® Enzymatic Chromatin IP 330 Kit (Cat: 9003, Cell Signalling Technology, Inc). Four million PC3 cells were grown in 150 mm dishes 331 either with or without 0.5 µg mL -1 doxycycline during 3 days. Cells from three 150 mm dishes were 332 cross-linked with 35% formaldehyde for 10 min at room temperature. Glycine was added to dishes 333 during 5 min at room temperature. Cells were then washed twice with ice-cold PBS, and scraped into 334 PBS+PMSF. Pelleted cells were lysed and nuclei were harvested following manufacturer's instructions. 335
Nuclear lysates were digested with micrococcal nuclease for 20 min at 37°C and then sonicated in 336 500μl aliquots on ice for 6 pulses of 20 s using a Branson sonicator. Cells were held on ice for at least 337 1 min between sonications. Lysates were clarified at 11,000 × g for 10 min at 4°C, and chromatin was 338 stored at -80°C. HA-Tag polyclonal antibody (Cat: C29F4, Cell Signalling Technology) and IgG antibody 339 (Cat: 2729, Cell Signalling Technology, Inc), were incubated overnight (4ºC) with rotation and protein 340 G magnetic beads were incubated 2hrs (4ºC). Washes and elution of chromatin were performed 341 following manufacturer's instructions. DNA quantification was carried out using a Viia7 Real-Time PCR 342
System (Applied Biosystems) with SybrGreen reagents and primers that amplify the predicted MITFA 343 binding region to CRYAB (region 1; For: ttgtttcctcgtagggcttg, Rev: tttcagagccaggagagagc-region 2; 344 For: tctggaatggtgatgtcagg, Rev: attgggtgtggacagaaagc) and ANGPTL4 (For: gttgacccggctcacaat, Rev: 345 ggaacagctcctggcaatc) as a negative binding control. 346
Whole genome gene expression characterization 347
Whole genome expression characterization was conducted using Human HT12 v4 BeadChips (Illumina 348
Inc.). In brief, cRNA synthesis was obtained with TargetAmp™ Nano-g™ Biotin-aRNA Labeling Kit for 349 the Illumina® System, Epicentre (Cat.Num. TAN07924) and subsequent amplification, labeling and 
Bioinformatic analysis and statistics 354
Database normalization: All the datasets used for the data mining analysis were downloaded from GEO 355 and TCGA. GEO-downloaded data was subjected to background correction, log2 transformation and 356 quartile normalization. In the case of using a pre-processed dataset, this normalization was reviewed 357 and corrected if required. TCGA data were downloaded as upper quartile normalized RSEM count, 358 which was been log2 transformed. 359
Quartile analysis in Disease Free Survival: Patients biopsies from primary tumours were organized into 360 four quartiles according to the expression of the gene of interest in three datasets. The recurrence of 361 the disease was selected as the event of interest. Kaplan-Meier estimator was used to perform the test 362 as it takes into account right-censoring, which occurs if a patient withdraws from a study. On the plot, 363 small vertical tick-marks indicate losses, where a patient's survival time has been right-censored. With 364 this estimator we obtained a survival curve, a graphical representation of the occurrence of the event 365 in the different groups, and a p-value that estimates the statistical power of the differences observed. Gene expression array data analysis: first, raw expression data were background-corrected, log2-386 transformed and quantile-normalized using the lumi R package7 387 , available through the Bioconductor repository. Probes with a "detection p-value" lower than 0.01 in at 388 least one sample were considered expressed. For the detection of differentially expressed genes, a 389 linear model was fitted to the probe data and empirical Bayes moderated t-statistics were calculated 390 using the limma package from Bioconductor. Only genes with differential fold-change (FC) >1.5 or <-391 1.5 and an adjusted p-value < 0.05 were considered as differentially expressed. 392
Accession numbers and datasets 393
Primary accessions: The transcriptomic data generated in this publication have been deposited in 394 NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number 395 GSE114345 (https://www. ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114345) . Valcarcel-Jimenez at al. Figure 4 
